MARKET

IRWD

IRWD

Ironwood
NASDAQ
10.40
+0.10
+0.97%
After Hours: 10.40 0 0.00% 16:02 12/07 EST
OPEN
10.33
PREV CLOSE
10.30
HIGH
10.43
LOW
10.25
VOLUME
1.43M
TURNOVER
0
52 WEEK HIGH
12.66
52 WEEK LOW
8.08
MARKET CAP
1.62B
P/E (TTM)
-1.6681
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at IRWD last week (1127-1201)?
Weekly Report · 3d ago
Ironwood Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for IRWD
NASDAQ · 6d ago
Tharimmune stock rockets 46% on positive Phase 1 data for PBC drug
Tharimmune stock rockets 46% on positive phase 1 data for its drug candidate th104 in the treatment of chronic pruritis in patients with primary biliary cholangitis. Tharimmune shares opened at $2.93 and closed at $4.79.
Seeking Alpha · 11/27 15:34
Weekly Report: what happened at IRWD last week (1120-1124)?
Weekly Report · 11/27 09:14
Ironwood: Statement of changes in beneficial ownership of securities
Press release · 11/22 23:11
Ironwood: Statement of changes in beneficial ownership of securities
Press release · 11/20 23:08
Weekly Report: what happened at IRWD last week (1113-1117)?
Weekly Report · 11/20 09:14
Ironwood: Report of proposed sale of securities
Press release · 11/18 01:21
More
About IRWD
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company, which is advancing the treatment of GI diseases and redefining the standard of care for GI patients. It develops and commercializes GI product opportunities in areas of significant unmet need, leveraging its demonstrated expertise and capabilities in GI diseases. LINZESS (linaclotide), its commercial product, in a class of GI medicines called guanylate cyclase type C agonists (GC-C agonists) and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC). LINZESS is available to adult men and women suffering from IBS-C or CIC in the United States and Mexico, IBS-C or chronic constipation in Japan, and IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries.

Webull offers Ironwood Pharmaceuticals, Inc. stock information, including NASDAQ: IRWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRWD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRWD stock methods without spending real money on the virtual paper trading platform.